Recce Pharmaceuticals Ltd. · ASX:RCE
Recce Pharmaceuticals — Shareholder Meeting (November 2026)
19 slides from Recce Pharmaceuticals's shareholder meeting presentation, Nov 6, 2026
Slide 1: AGM Presentation
al use only AGM Presentation ASX:RCE | FSE:R9Q 6 November 2026 0
Slide 2: Disclaimer
Disclaimer DISCLAIMER FUTURE MATTERS This presentation has been prepared by Recce Pharmaceuticals Ltd (the “Company”). It does This presentation contains reference to certain intentions, expectations, future plans, strategy and prospects of not purport to contain all the information that a prospecti
Slide 3: Company Overview
al use only Company Overview
Slide 4: Recce Pharmaceuticals – Company Overview
Recce Pharmaceuticals – Company Overview Recce Pharmaceuticals is an Australian clinical stage anti-infective company Products address the global healthcare crisis of antibiotic resistance: working faster than traditional antibiotics and against multidrug resistant bacteria - Patient dosing well und
Slide 5: Board and Management Structure
Board and Management Structure Dr John Prendergast – Chairman BSc (Hons), MSc (UNSW), PhD (UNSW), CSS (HU) Michele Dilizia – Executive Director & Chief Scientific Officer BSc (Med Sci), Grad Dip Bus (Mkting), BA (Journ), GAICD, MASM US-based, current Chairman and Co-founder of Palatin Technologies,
Slide 6: Capital Structure and Share Price
Capital Structure and Share Price Recce Pharmaceuticals Ltd is a clinical-stage biotech company with a new class of novel synthetic anti-infectives Capital Structure – November 2026 RCE Share Price and Volume Chart – 12 Months (price shown in AUD) ASX & FSE Code RCE, R9Q 1,600,000 $0.80 Share Price
Slide 7: Company Pipeline driven by 1st approval in Diabetic Foot Infections
Company Pipeline driven by 1st approval in Diabetic Foot Infections 2026 2027 Core Programs 155-patient R327G R327G Registrational Phase 3 trial recruitment interim analysis registrable registrable and dosing continue uninterrupted and readout in Indonesia in ASEAN R327G Topical Diabetic foot infect
Slide 8: Commercial & Licensing
al use only Commercial & Licensing 7
Slide 9: R327G Key Addressable DFI Markets
R327G Key Addressable DFI Markets Estimated patients with Potential Total Key market mild or moderate DFI per Commercial partner Addressable Market year Australia & NZ al use only 1.79m diabetic adults1 34,400 Approx. A$73m Binding exclusive licence Indonesia 20.4m diabetic adults1 391,700 Approx. A
Slide 10: Australia and New Zealand Licence Agreement
Australia and New Zealand Licence Agreement Recce has signed a binding exclusive licence agreement with Arrotex Pharmaceuticals to commercialise R327G A direct commercial route for R327G in Australia and New Zealand Agreement Highlights al use only Partnership with Arrotex Pharmaceuticals Commercial
Slide 11: Middle Eastern Pharmaceutical Company Term Sheet
Middle Eastern Pharmaceutical Company Term Sheet Recce has signed a non-binding term sheet with a leading Middle Eastern Pharmaceutical Company for a 10-year exclusive multi-country licensing agreement for the licensing of R327G through the MENA region Term Sheet Highlights • The MENA region has a d
Slide 12: Selected ASX Companies with active Phase Programs
Selected ASX Companies with active Phase 3 Programs Eight ASX companies are advancing Phase 3 therapeutic trials — four have failed since 2025 Active Phase 3 Programs – ASX Companies Market Cap (A$) Phase 3 Failures Since 2025 Telix Pharmaceuticals (ASX: TLX) 4.53B Paradigm Biopharmaceuticals (ASX:
Slide 13: RECCE Topical Gel
al use only RECCE® 327 Topical Gel 12
Slide 14: Dual Phase Clinical Trial Strategy
Dual Phase 3 Clinical Trial Strategy Two Phase 3 Clinical Trials, in Australia and Indonesia Indonesia Phase 3 Australia Phase 3 Registrational, multi-centre, double-blind, placebo-controlled Conducted to TGA and US FDA regulatory standards, Active- comparator design: R327G versus one of four physic
Slide 15: Indonesia Phase 3: Independent DMC Review Underway
Indonesia Phase 3: Independent DMC Review Underway Blinded Data across 75 patients has shown • Review of the blinded data indicates strong efficacy 75 90 al use only across the study population • RECCE® 327 Gel (R327G) continues to demonstrate Patients submitted for Patients currently enrolled an ex
Slide 16: Phase 3 DFI Clinical Trial in Australia
Phase 3 DFI Clinical Trial in Australia HREC approves protocol amendment adding randomised, active-controlled, non-inferiority + superiority component Protocol amendment adds moderate DFI. Mild and Moderate DFI together represent 80% of DFI presentations. al use only Head-to-head comparison agains
Slide 17: Progress with the U.S. Department of War
Progress with the U.S. Department of War Collaboration with the U.S. Department of War in advancing next-generation of anti-infectives U.S. Army Medical CDMRP Grant US$2 million 1st CRADA Research Institute of 2nd CRADA – Feb 2026 Infectious Diseases al use only (USAMRIID) Congressionally Directed M
Slide 18: Robust Worldwide Intellectual Property Portfolio
Robust Worldwide Intellectual Property Portfolio Recce’s patent portfolio contains over 40 patents and patent applications in the world’s major markets. Patent Patent Patent Patent Filed Expiry Expiry Expiry Expiry Family 1 Family 2 Family 3 Family 4 Australia ✓ 2028 ✓ 2037 ✓ 2037 ✓ 2041 Family 1 gr
Slide 19: Thank you
al use only Thank you recce.com.au
Recce Pharmaceuticals — Shareholder Meeting (November 2026) on 6ix